Cancer Control最新文献

{"title":"A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer.","authors":"Chongshan Gu, Yingjian He, Nan Zhang, Yiqiang Liu, Jinfeng Li, Tianfeng Wang, Tie Fan, Zhaoqing Fan, Tao Ouyang","doi":"10.1177/10732748251339958","DOIUrl":"https://doi.org/10.1177/10732748251339958","url":null,"abstract":"<p><p>ObjectivesNeoadjuvant endocrine therapy (NET) has demonstrated efficacy in postmenopausal patients with hormone-responsive and HER2-negative breast cancer. However, few data are available on NET in premenopausal women. This trial was designed to compare the effectiveness of neoadjuvant chemotherapy (NCT) with NET in premenopausal patients with hormone-responsive, HER2-negative, and lymph node-negative breast cancer.MethodsIn this prospective, randomized study, premenopausal patients with hormone-responsive, HER2-negative, and lymph node-negative breast cancer were recruited. The enrolled patients were randomly assigned (1:1) to receive either NCT or NET with goserelin and tamoxifen, followed by goserelin and anastrozole. The primary purpose was to evaluate the non-inferiority of NET to NCT using a clinical response rate assessed by ultrasound.ResultsA total of 68 patients were assigned to receive either NCT (n = 31) or NET (n = 37). The clinical response rate was 16.1% for NCT and 35.1% for NET (estimated difference 19.0%, 95%CI: -1.1%-39.1%, non-inferior <i>P</i> = 0.002). The rates of breast-conserving surgery were not significantly different between the NCT and NET groups (90.3% vs 83.8%, <i>P</i> = 0.494).ConclusionsA 35.1% clinical response rate was observed in premenopausal patients after NET. However, this study was underpowered to conclude the non-inferiority of NET to NCT because of its early closure.Trial registrationClinicalTrials.gov NCT02535221.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251339958"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Totally Implantable Access Ports Associated Complications in Breast Cancer Patients.","authors":"Yangfan Fan, Xiaohang Ye, Fangfang Chen, Fang Wan, Dianlei Liu, Tao Zhang, Jingpei Long","doi":"10.1177/10732748251336407","DOIUrl":"https://doi.org/10.1177/10732748251336407","url":null,"abstract":"<p><p>ObjectiveTo investigate the risk factors for complications in breast cancer patients with totally implantable access ports (TIAPs).MethodsThis retrospective case-control study involved 471 breast cancer (BC) patients who received TIAPs during chemotherapy. We compared the demographic and clinical characteristics of patients with complications to those without, analyzed independent risk factors using binary logistic regression, and identified differences in complication rates based on catheterization site.ResultsThe most frequent complication was catheter malposition, followed by infection, thrombosis, hemothorax, and port rotation. Complications were more common in right-side BC cases (<i>P</i> = .026) and with left-side insertions (<i>P</i> = .012). Binary logistic regression identified independent risk factors for complications: catheter tip location (OR = 0.599, <i>P</i> = .013), and catheterization site (OR = 0.319, <i>P</i> = .019). Notably, left-side insertion significantly increased the risk of overall complications and catheter malposition compared to right-side insertion (OR = 3.534, <i>P</i> = .008; OR = 5.624, <i>P</i> = .004, respectively).ConclusionCatheter tip location and catheterization site independently affect complications and catheter malposition. For TIAPs implantation, particularly on the left side, a lower catheter tip location is advised to reduce complications and enhance safety.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336407"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives.","authors":"Xiaoni Jin, Weixing Zhao, Guoyuan Li, Jun Jiang","doi":"10.1177/10732748251334434","DOIUrl":"https://doi.org/10.1177/10732748251334434","url":null,"abstract":"<p><p>BackgroundLimited-stage small cell lung cancer (LS-SCLC) is a highly aggressive tumor characterized by a poor prognosis. While concurrent chemoradiotherapy (CCRT) remains the standard treatment, the high rates of recurrence and poor long-term survival highlight the pressing need for novel therapeutic approaches.PurposeIn recent years, the introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has opened new avenues for the treatment of LS-SCLC. This review highlights the clinical advancements of ICIs in CCRT, consolidation therapy, and neoadjuvant therapy, emphasizing their potential to improve progression-free survival (PFS) and overall survival (OS). This review also discusses management of immunotherapy-related side effects.Research DesignThis is a review article that synthesizes recent research findings on immunotherapy for LS-SCLC.Study SampleNot applicable (review of existing literature).Data Collection and/or AnalysisThis review summarizes key studies exploring the application of immunotherapy in limited-stage small cell lung cancer.Additionally, it examines the role of the tumor microenvironment, tumor mutation burden (TMB), and Programmed cell death 1 ligand 1(PD-L1) as biomarkers for predicting the efficacy of immunotherapy.ResultsThis review emphasizes their potential to improve PFS and OS.ConclusionsDespite the significant advancements in research, the use of ICIs in LS-SCLC continues to face challenges, including the identification of optimal treatment regimens, validation of long-term efficacy, and development of personalized predictive biomarkers. Future research should prioritize large-scale, multicenter clinical trials to refine combination therapy strategies, establish customized treatment approaches, and enhance patient outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251334434"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Projections of Early-Onset Colorectal Cancer Burden in China, 1990-2036: Findings From the Global Burden of Disease 2021 Study.","authors":"Tianze Huang, Jianfu Qiu, Changhao Wang, Xiang Ma, Duo Liu, Jian Cai","doi":"10.1177/10732748251341524","DOIUrl":"https://doi.org/10.1177/10732748251341524","url":null,"abstract":"<p><p>BackgroundThe incidence and prevalence of early-onset colorectal cancer (EO-CRC), defined as colorectal cancer diagnosed before the age of 50, are increasing globally. However, the current status and trends of the disease burden of EO-CRC in China, including incidence, prevalence, mortality, and disability-adjusted life-years (DALYs), are not well understood. This study aimed to analyze the epidemiological trends of EO-CRC in China from 1990 to 2021 and to project its future burden.MethodsWe analyzed data from the Global Burden of Disease (GBD) 2021 study to assess the trends in incidence, prevalence, mortality, and DALYs of EO-CRC in China from 1990 to 2021. Joinpoint regression analysis was used to identify significant changes in trends. Age-period-cohort (APC) analysis was conducted to disentangle the effects of age, period, and birth cohort. The Bayesian APC model was employed to project the burden of EO-CRC up to 2036.ResultsFrom 1990 to 2021, the absolute number of EO-CRC incident and prevalent cases in China increased substantially. The age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) also rose significantly, with an accelerated increase after 2007 in men and after 2015 in women. In contrast, the age-standardized mortality rate (ASMR) and age-standardized DALYs rate (AS-DALYs) generally declined; however, a concerning reversal of this trend has been observed in recent years. Incidence, prevalence, mortality and DALYs rates all showed significant age, period, and cohort effects. Projections indicate that ASIR and ASPR will continue to rise until 2036, especially in males, and the disparity in disease burden between men and women is expected to widen.ConclusionThe disease burden of EO-CRC in China has increased significantly and is rising rapidly, particularly among males. Further research is essential to fully understand the factors contributing to the increased incidence of EO-CRC and to develop effective mitigation strategies.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341524"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.","authors":"Jia-Jun Hui, Han-Lu Yan, Sheng-Jun Ding, Bao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang","doi":"10.1177/10732748251320822","DOIUrl":"10.1177/10732748251320822","url":null,"abstract":"<p><strong>Background: </strong>This cohort study aimed to evaluate the impact of tumor burden (TB) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>Data from the POPLAR and OAK trials were extracted as the training and validation cohorts, respectively. TB was defined as the sum of the longest dimensions (blSLD) of measurable target lesions as per RECIST v1.1. The Kaplan-Meier curves and multivariate Cox regression analyses were performed to assess the association between TB with blood-tested tumor mutation burden (bTMB), PD-L1 expression, and survival outcomes. Additionally, random forest algorithms analysis was performed to evaluate the accuracy of TB in predicting 12-month mortality of NSCLC patients received atezolizumab.</p><p><strong>Results: </strong>A total of 105 patients from the POPLAR trial and 322 patients from the OAK trial were recruited in the training and validation sets, respectively. Patients with TB-L have significantly better OS than those with TB-H in the training (mOS: 15.8 months vs 6.93 months) as well as the validation (mOS: 16.0 months vs 7.59 months) cohort. The multivariate Cox regression analysis indicated that TB is an independent biomarker for OS prediction, regardless of bTMB, PD-L1 expression, and number of metastasis sites. The impact of TB on 12-month mortality was expected to be stronger with the increase of TB, suggesting that patients with a high tumor burden experienced a detrimental effect on 12-month mortality.</p><p><strong>Conclusion: </strong>TB may act as a prognostic biomarker for clinical benefit in NSCLC patients treated with immunotherapy alone. This may be potentially effective for predicting the efficacy of immunotherapy-based regimens.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320822"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Pathological Features of \"Crawling-type\" Early Gastric Carcinoma: A Retrospective Series of Eight Cases.","authors":"Kehan Li, Xiaofeng Zhuang, Bingyue Yao, Li Zhang, Qinwei Xu, Tao Chen, Jia Cao","doi":"10.1177/10732748251319486","DOIUrl":"10.1177/10732748251319486","url":null,"abstract":"<p><strong>Background: </strong>\"Crawling-type\" early gastric carcinoma (EGC) is a rare subtype of gastric cancer (GC) that is challenging to diagnose at an early stage due to its low-grade nuclear heterogeneity and morphology that mimics intestinal metaplasia. This study aimed to explore the clinical characteristics and pathological features of patients with crawling-type EGC.</p><p><strong>Methods: </strong>This case series study retrospectively included patients with crawling-type EGC who underwent endoscopic submucosal dissection (ESD) or gastrectomy at the East Hospital Affiliated to Tongji University between January 2019 and March 2022.</p><p><strong>Results: </strong>8 patients (mean age 63.5 ± 7.8 years) were included: 4 underwent ESD, and 4 underwent partial gastrectomy. In 4 patients, the tumors were primarily located in the gastric cardia and the basal gland area of the upper stomach, while the other 4 patients had tumors in the antral region. Preoperative gastroscopy revealed atrophic gastritis and intestinal metaplasia in all patients. The lesions were generally flat in morphology. Submucosal infiltration was found in only one case. Signet ring cells were present in the tumors of 5 patients. The mucinous type was observed in 7 patients. Seven tumors were of the gastrointestinal mixed type. Curative resection was achieved in all patients. No recurrence events were observed in any patient at 1 year after surgery.</p><p><strong>Conclusions: </strong>The crawling-type EGC may exhibit distinct clinical characteristics and pathological features compared with classical GC. Curative resection was achieved in all patients. The short-term prognosis of surgical treatment may be favorable.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319486"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma.","authors":"Haoru Wang, Xin Chen, Ling He, Jinhua Cai","doi":"10.1177/10732748251315883","DOIUrl":"10.1177/10732748251315883","url":null,"abstract":"<p><strong>Background: </strong>This study compared anatomical imaging features between high-risk and non-high-risk groups in neuroblastoma with at least one image-defined risk factor (IDRF). It also assessed the diagnostic performance of these features in identifying the high-risk group.</p><p><strong>Methods: </strong>A retrospective analysis of neuroblastoma patients with at least one IDRF was conducted. Imaging features, including estimated tumor volume and IDRFs, were compared between the two groups. The diagnostic performance of these features was assessed using receiver operating characteristic (ROC) curves, and the areas under the ROC curves (AUCs) along with their 95% confidence intervals (CIs) were calculated. Additionally, to internally validate their diagnostic performance, the bootstrap resampling method with 1000 bootstrap resamples was employed.</p><p><strong>Results: </strong>The study included 255 patients (185 high-risk cases, 70 non-high-risk cases). Significant differences were found in estimated tumor volume and IDRF number between the high-risk and non-high-risk groups (<i>P</i> < 0.001). The estimated tumor volume and the IDRF number-based cluster were independent risk factors, and their combination achieved an AUC of 0.801 (95% CI: 0.747-0.848) for high-risk group diagnosis, with the average AUC of the 1000 bootstrap samples of 0.800 (95% CI: 0.798-0.802). In abdominal lesions, specific IDRF categories differed between high-risk and non-high-risk groups (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Our study reveals anatomical imaging differences between high-risk and non-high-risk groups in neuroblastoma with at least one IDRF.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251315883"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Mechanisms and Therapeutic Targets of Hepatitis B Virus Pre-S Mutant-Associated Hepatocellular Carcinoma Tumorigenesis.","authors":"Long-Bin Jeng, Wen-Ling Chan, Chiao-Fang Teng","doi":"10.1177/10732748251320492","DOIUrl":"10.1177/10732748251320492","url":null,"abstract":"<p><p><b>Background:</b> Despite significant progress in diagnosis and therapeutics, hepatocellular carcinoma (HCC) is still among the most commonly occurring and life-taking human cancers globally, raising an urgent need for discovering effective therapeutic targets.<b>Purpose:</b> Chronic hepatitis B virus (HBV) infection is a major etiological factor associated with HCC development, progression, and prognosis. Pre-S mutants are naturally occurring mutated forms of HBV large surface proteins and predict a higher risk of HCC development and recurrence. Moreover, pre-S mutants function as important HBV oncoproteins which can promote HCC tumorigenesis through initiating a variety of oncogenic signaling pathways. Targeting pre-S mutant-induced oncogenic signaling pathways displays therapeutic potential in HCC.<b>Research Design:</b> This review summarizes the underlying molecular mechanisms of pre-S mutant-associated HCC tumorigenesis and highlights their potential in serving as therapeutic targets for HCC.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320492"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: From Diagnosis to Survivorship: How the Tumor Boards Facilitation Forum (TEFF) Shapes the Breast Cancer Journey in Pakistan.","authors":"","doi":"10.1177/10732748251331409","DOIUrl":"10.1177/10732748251331409","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331409"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Germline Variants in the <i>BRCA2</i> Gene and Their Association With Prostate Cancer Risk in Polish Men: A Case-Control Study.","authors":"Marta Heise, Piotr Jarzemski, Julia Kuk","doi":"10.1177/10732748251327720","DOIUrl":"https://doi.org/10.1177/10732748251327720","url":null,"abstract":"<p><p>ObjectivesCurrently, prostate cancer (PC) is the most common medical problem endangering men's health and life worldwide. We tested the association of detected germline variants in <i>BRCA2</i> with PC risk and estimated their impact on the clinical course of the disease, including overall survival time, in Polish men with localized PC that qualified for radical prostatectomy (RP).Materials and MethodsDNA of 97 PC patients from various age groups and with different disease stages was analyzed. Control DNA samples consisted of 100 male volunteers without PC that were age-matched to the study group. Next Generation Sequencing (NGS) and Sanger sequencing were used for variant detection.ResultsFive rare variants of the <i>BRCA2</i> gene were detected in single PC patients. There were four substitutions (c.8010G>C, c.682-32A>G, c.9257-75G>C, c.516+17G>C) and one deletion (c.6393_6396del). Among the detected variants, one was pathogenic, one was a variant of uncertain significance (VUS), and three were likely benign. The c.8010G>C was a new variant. In the carrier of the c.6393_6396del pathogenic variant, PC was diagnosed at the T3 stage and the patient survived 48 months after PC confirmation (the date of biopsy).ConclusionsThe <i>BRCA2</i> c.6393_6396del pathogenic variant demonstrates an association with clinical features of the disease (GS and TNM) and shorter survival of patients with localized prostate cancer that qualified for RP. Additionally, our findings suggest that multi-organ cancer aggregation in a family, including prostate cancer aggregation in close relatives, and young age at cancer onset should be taken into consideration by clinicians as an indication to refer patients to molecular testing.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251327720"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}